Boehringer Ingelheim

Every breath counts - because the right diagnosis at the right time is the gateway to care. At #WHA79 in Geneva, our Country Manager Germany Médard Schoenmaeckers joined discussions on how we turn global commitments into real-world delivery - including the 2025 WHO Lung Health Resolution and the wider NCD agenda. The Resolution is a landmark step - and the first time pulmonary fibrosis has been explicitly acknowledged in global health policy. But the real test is implementation: improving awareness, strengthening pathways to timely and accurate diagnosis, and ensuring high-quality care. Progress depends on effective collaboration between governments, civil society, multilateral organizations and industry. Here are a few key takeaways from the session - and what needs to happen next.  #LungHealth #PulmonaryFibrosis #ChronicRespiratoryDiseases #HealthPolicy #NCDs

A routine dog check-up involves hundreds of small decisions.     Veterinarians observe small changes in behavior from the second an animal enters the clinic. They combine experience and years of training to assess each dog individually - adapting care in subtle ways that can go unnoticed if you’re not a vet yourself. Yet that’s how routine visits become personalized care.     If you own a dog, don't be afraid to ask questions during appointments and make sure you get as much expert advice as possible. Bringing a list can help to cover everything that matters for your dog's health. 📋Download our guide for pet owners and be prepared for the next check-up: https://lnkd.in/dQViECWY

At #ATS2026, it’s been inspiring to hear directly from experts about new opportunities in #PulmonaryFibrosis care. With the unmet need in the field still high, it’s meaningful to see innovation opening new opportunities for patients and prescribers. #LifeForward

Spoiler alert. You don’t need a lab coat to make an impact here. Despite being a research-based pharmaceutical company, not all of us have a background in natural science. From pharmaceutical sciences and data, to IT and marketing, it's this blend of talent that drives our groundbreaking work. Apply now on our careers page: https://lnkd.in/guZFjt7u #LifeForward

#NEWS: Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved our treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).  Both conditions lead to an accelerated decline in lung function, massively impacting quality of life and claim many lives within only a few years of diagnosis.   Learn more: https://lnkd.in/daYkKZBP   #LifeForward #PulmonaryFibrosis

Living with idiopathic pulmonary fibrosis can feel isolating for both people living with the condition and those who care for them. In this video, Ron and his wife Maxine share how connecting with a support group helped them feel understood, supported, and less alone while navigating life with #IPF. Learn more about their story and the role support groups can play for people living with IPF and their carers: https://lnkd.in/dy_56urD   #LifeForward #PulmonaryFibrosis

Through our collaboration with Mary Tyler Moore Vision Initiative, we’re working alongside universities, foundations, and pharmaceutical and biotech companies to better detect, prevent, and treat vision loss from diabetes.   Learn why preserving real-world vision must remain at the center of innovation 👇 #EyeHealth

A routine cat check-up involves hundreds of small decisions.    Veterinarians observe small changes in behavior from the second an animal enters the clinic. They combine experience and years of training to assess each cat individually - adapting care in subtle ways that can go unnoticed if you’re not a vet yourself. Yet that’s how routine visits become personalized care.     If you own a cat, don't be afraid to ask questions during appointments and make sure you get as much expert advice as possible. Bringing a list can help to cover everything that matters for your cat's health. 📋Download a guide for pet owners and be prepared for the next check-up: https://lnkd.in/dQViECWY

Today, we announced a new global licensing agreement with Immunitas Therapeutics to advance a preclinical antibody program for inflammatory and autoimmune diseases.   This first-in-class program selectively targets pathogenic immune cells at inflammation sites. With this approach, there’s a potential to deliver more durable, long-lasting disease control across a range of chronic conditions.   Learn more about what this could mean for patients: https://lnkd.in/dd27jndu #Biopharma #Immunology #AutoimuneDiseases

“When patients speak, decision-makers listen,” says Christine Cockburn, CEO of Rare Cancers Australia. This belief is at the heart of why we're empowering patient organizations to advocate for systemic change and equitable access to care. As part of this effort, we co-created the white paper: "Real Voices, Better Choices", with Christine and a wider editorial board of patient advocates. It's a practical resource for policymakers and advocates to formalize patient participation and drive better health outcomes for everyone.  Learn more about the context of the white paper here: https://lnkd.in/d_JQk-GA, and take a moment to think about how you can help drive #PatientPoweredProgress.